PressApril 24, 2024 MindBio Landmark Sleep Research Published in Prestigious Nature Portfolio Journal Translational Psychiatry
PressApril 24, 2024 Algernon NeuroScience and the Centre for Human Drug Research to Present DMT Phase 1 Stroke Clinical Data at the Interdisciplinary Conference on Psychedelic Research June 6 – 8th, 2024
PressApril 24, 2024 atai Life Sciences Announces Dosing of First Patient in Part 2 of Beckley Psytech’s Phase 2a Study Exploring BPL-003 Adjunctive to SSRIs in Patients with Treatment Resistant Depression
PressApril 23, 2024 Revive Therapeutics Announces Type C Meeting Request Granted by FDA for Clinical Study of Bucillamine to Treat Long COVID
PressApril 23, 2024 Red Light Holland Initiates Psilocybin Extraction Phase with PharmAla Following Successful Testing and Preparation by CCrest Labs
PressApril 23, 2024 Optimi Health and Kwantlen Polytechnic University Applied Genomics Centre Partner to Advance Mushroom Science and Research
PressApril 22, 2024 FSD Pharma Provides Another Update on Celly Nu’s Anticipated Launch of unbuzzd(TM)
PressApril 18, 2024 Revive Therapeutics Announces FDA Acceptance of Meeting Request for Long COVID Diagnostic Product
PressApril 18, 2024 Cybin Announces Publication of Research Manuscript in the Journal of Medicinal Chemistry
PressApril 17, 2024 Clearmind Medicine Announces Exclusive Licensing Agreement for Generation 3.0 Psychedelic Compounds for the Treatment of Mental Disorders
PressApril 17, 2024 Atai Life Sciences Announces the Publication of Beckley Psytech’s Phase 1 Study of BPL-003 in the Journal of Psychopharmacology
PressApril 17, 2024 Cedar Clinical Research selected as clinical research site for Cybin’s Phase 3 Study of CYB003
PressApril 16, 2024 Cybin Announces Grant of Additional U.S. Patent in Support of its CYB003 Breakthrough Therapy Program for Major Depressive Disorder
PressApril 16, 2024 PharmaDrug’s SecureDose Announces the Advancement of Process Development of Its Biosynthetic Formulation of Pharmaceutical Grade Cocaine
PressApril 16, 2024 Psyence Group’s NASDAQ Listed Associate, Psyence Biomedical Partners with Fluence and iNGENū CRO to Train Research Therapists for Phase IIb Psilocybin Trial
PressApril 16, 2024 Optimi Health Achieves Milestone: Completes In-House Production of MDMA Active Pharmaceutical Ingredient (API)
PressApril 12, 2024 Red Light Holland’s Largest Psilocybin Shipment Received by CCrest Labs in Montreal with Health Canada Approved Import Permit
PressApril 11, 2024 Algernon Pharmaceuticals CEO Christopher J. Moreau to Be Featured on Radius Research’s Pitch, Deep Dive and Q&A Webinar on April 16th, 2024
